Advantag of ingestion administration way is its easiness even when applied at home. But with their help necessary treatment concentration in blood cannot be always quickly achieve buy antibiotics online transaction is carried out on anonymity and mutual profit principles, and in addition customers will be positively surprised with quality and speed of service.

I04.yizimg.com

LABORATORIES
Estrogen Receptor and Progesterone Receptor (duo pack)
Cat. No. VP-E612
Intended Use: FOR RESEARCH USE ONLY
The Estrogen Receptor and Progesterone Receptorduo pack contains: 1 x 0.5 ml Estrogen Receptor (clone 6F11)1 x 0.5 ml Progesterone Receptor (clone 1A6) Vector Laboratories, Inc., 30 Ingold Road, Burlingame, CA 94010 U.S.A.
Tel: (650)697-3600 • Fax (650)697-0339 • Email: [email protected] • Website: www.vectorlabs.com LABORATORIES
Antibody to Estrogen Receptor
Product Specifications
Description
Applications:
Estrogen Receptor mouse monoclonal antibody
Immunohistochemistry
Immunoglobulin class:
Immunogen:
Prokaryotic recombinant protein representing the fulllength alpha form of the estrogen receptor molecule.
Epitope:
Western blotting
Presentation:
Lyophilized tissue culture supernatant containing 15mM sodium azide. Reconstitute with 0.5 ml of distilled water.
Species cross-reactivity:
* Recommended dilutions using VECTASTAIN® Elite Functional Aspects:
Storage Conditions:
Estrogen receptor (ER) is expressed in a variety of Keep unopened vial at 2 - 8 °C for 1 year. Once different tissues but is found most prominently in the opened it is recommended that the stock solution be female reproductive tract. A large amount of research aliquoted and quick frozen and stored at -20 °C. Do has focused on the differential expression of ER in human breast cancer. This antibody will help detectthe presence of ER in tissues and cell lines.
Selected References
Braidman I P, Baris C, Selby P L, et al. Preliminary report of impaired oestrogen receptor-a expression in bone, but no involvement of androgen
receptor, in male idiopathic osteoporosis. Journal of Pathology. 192: 90-96 (2000).
Im S, Lee E-S, Kim W, et al. Expression of progesterone receptor in human keratinocytes. Journal of Korean Medical Science. 15: 647-654 (2000).
Leake R, Barnes D, Pinder S, et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. Journal of Clinical
Pathology. 53 (8): 634-635 (2000).
Kawabata K, Watanabe K, Ozaki S, et al. Utility of the paraffin-embedded section method on the detection of estrogen receptor from breast cancer
tissues - comparison of the paraffin-embedded section method (6F11 and 1D5) with frozen section (H222) and dextran-coated charcoal (DCC) ones.
Rinsho Byori. 47 (8): 767-773 (1999).
Bevitt D J, Milton I D, Piggot N, et al. New monoclonal antibodies to oestrogen and progestrone receptors effective for paraffin section immunohis-
tochemistry. Journal of Pathology. 183: 228-232 (1997).
Hurlimann J, Gebhard S and Gomez F. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and Cathepsin D in invasive ductal breast
carcinomas. Histopathology. 23: 239-248 (1993).
Snead D R J, Bell J A, Dixon A R, et al. Methodology of immunohistological detection of oestrogen receptor in human breast carcinoma in formalin-
fixed, paraffin-embedded tissue: a comparison with frozen section methodology. Histopathology. 23: 233-238 (1993).
Clark G M and McGuire W L. The clinical usefulness of oestrogen-receptor and other markers of hormone dependence. Proceedings of the Royal
Society of Edinburgh. 95B: 145-150 (1989).
Henry J A, Angus B and Horne C H W. Oestrogen receptor and oestrogen regulated proteins in human breast cancer: a review. KEIO Journal of
Medicine. 38: 241-261 (1989).
Shintaku P and Said J W. Detection of estrogen receptors with monoclonal antibodies in routinely processed formalin-fixed paraffin sections of
breast carcinoma. American Journal of Clinical Pathology. 87: 161-167 (1987).
Mason B H, Holdaway I M, Mullins P R, et al. Progesterone and oestrogen receptors as prognostic variables in breast cancer. Cancer Research.
43:2985-2990 (1983).
Stefanini M, De Martino C and Zamboni L. Fixation of ejaculated spermatozoa for electron microscopy. Nature. 216: 173-174 (1967).
VP-E612 is recommended FOR PROFESSIONAL AND RESEARCH USE ONLY Vector Laboratories, Inc., 30 Ingold Road, Burlingame, CA 94010 U.S.A.
Tel: (650)697-3600 • Fax (650)697-0339 • Email: [email protected] • Website: www.vectorlabs.com LABORATORIES
Antibody to Progesterone Receptor
Product Specifications
Description
Applications:
Progesterone Receptor mouse monoclonal antibody
Immunohistochemistry
Immunoglobulin class:
Immunogen:
Synthetic peptide of human progesterone receptor.
Uterus, breast carcinoma. Nuclearstaining pattern.
Epitope:
Western blotting
Presentation:
Lyophilized tissue culture supernatant containing 15mM sodium azide. Reconstitute with 0.5 ml of distilled water.
Species cross-reactivity:
* Recommended dilutions using VECTASTAIN® Elite®ABC Kits.
Storage Conditions:
Keep unopened vial at 2 - 8 °C for 1 year. Once
Functional Aspects:
opened it is recommended that the stock solution be Progesterone receptor (PR) is expressed in a variety aliquoted and quick frozen and stored at -20 °C. Do of different tissues but is found most prominently in the female reproductive tract. A large amount of researchhas focused on the differential expression of PR inhuman breast and uterine cancers. This antibody willhelp detect the presence of PR in tissues and cell lines.
Selected References
Mote P A, Johnston J F, Manninen T, et al. Detection of progesterone receptor forms A and B by immunohistochemical analysis. Journal of Clinical
Pathology. 54: 624-630 (2001).
Blakeman P J, Hilton P and Bulmer J N. Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to
oestrogen status. BJU Int. 86 (1): 32-38 (2000).
Leake R, Barnes D, Pinder S, et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. Journal of Clinical
Pathology. 53 (8): 634-635 (2000).
Clark G M and McGuire W L. The clinical usefulness of oestrogen-receptor and other markers of hormone dependence. Proceedings of the Royal
Society of Edinburgh. 95B: 145-150 (1989).
Giri D D, Goepel J R, Rogers K, et al. Immunohistological demonstration of progesterone receptor in breast carcinomas: correlation with radioligand
binding assays and oestrogen receptor immunohistology. Journal of Clinical Pathology. 41: 444-447 (1988).
Raemakers J, Beex L, Pieters G, et al. Progesterone receptor activity and the response to first endocrine therapy. European Journal of Cancer and
Clinical Oncology. 23(4): 443-447 (1987).
Gross G, Clark G, Chamness G, et al. Multiple progesterone receptor assays in cancer of the breast. Cancer Research. 44: 837-840 (1984).
Clark G M, McGuire W L, Hubay C A, et al. Progesterone receptors as a prognostic factor in stage II breast cancer. The New England Journal of
Medicine. 309(22): 1343-1347 (1983).
Mason B H, Holdaway I M, Mullins P R, et al. Progesterone and oestrogen receptors as prognostic variables in breast cancer. Cancer Research. 43:
2985-2990 (1983).
Stewart J, King R, Hayward J, et al. Oestrogen and progesterone receptors: correlation of response rates, sites and timing of analysis. Breast Cancer
Research and Treatment. 2: 243-251 (1982).
Stefanini M, De Martino C and Zamboni L. Fixation of ejaculated spermatozoa for electron microscopy. Nature. 216: 173-174 (1967).
VP-E612 is recommended FOR PROFESSIONAL AND RESEARCH USE ONLY Vector Laboratories, Inc., 30 Ingold Road, Burlingame, CA 94010 U.S.A.
Tel: (650)697-3600 • Fax (650)697-0339 • Email: [email protected] • Website: www.vectorlabs.com

Source: http://i04.yizimg.com/upload/315806/VPE612.pdf

Microsoft word - pgx ib.docx

Pharmacogenomics: Hope and Hype Physicians and researchers have expressed great optimism and confidence in pharmacogenetics merging into medical practice. As the science progresses, it may become feasible that, rather than treating a patient with therapies that may not work for them – or could be toxic – doctors armed with pharmacogenetic know-how will tailor treatments. This approach h

Mattioli _ultrapeel ii-tranderm.cdr

Ultrapeel ® II plus Transderm ® Meso ® System is a powereddrug-delivery system that has been FDA approved for theFDA cleared as alternative to injections. “local administration of ionic drug solutions into the body formedical purposes and can be used as an alternative to injec-Ultrapeel® Transderm® Meso® System uses Dermoelectro-Current delivery perception protected. poration® Techn

Copyright © 2010-2014 Medical Articles